We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio There was no significant difference in ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

It is essential that health care providers identify predictors of excess mortality in patients with T2D to optimally target risk-reduction strategies. Patients with T2D would benefit from more ...

Investigators found that in patients with diabetes and cancer, sodium glucose cotransporter-2 inhibitors were associated with a higher risk of diabetic ketoacidosis and fracture and a lower risk of ...

Although good glucose control in type 2 diabetes significantly improves patient outcomes, having many options for oral therapy can complicate treatment decisions. In this context, a drug’s risk of ...

We thank Dr. Mithoowani and colleagues for their excellent review on the investigation and management of erythrocytosis,1 which provides a comprehensive overview and approach to a common presentation ...

As the tide of obesity and its complications are on the rise, there is an urgent need for new drugs with weight-lowering and beneficial metabolic properties. Obesity-related disorders, such as ...

In work that could someday improve treatments for epilepsy, scientists have the first three-dimensional structure of a member of a large family of human proteins that carry charged particles -- ions - ...